Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of GSK6097608 alone and with anticancer antibodies in advanced solid tumors
jRCT2031210338Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of nelistotug, dostarlimab, belrestotug and cobolimab in Nonhematologic neoplasms (5 arms), sponsored by GSK. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants with adverse events and 1 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
nelistotugdostarlimabbelrestotugcobolimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210338.